Who are Kyverna Therapeutics's investors?

Kyverna Therapeutics's investors include Vida Ventures, Westlake Village BioPartners.

Kyverna Therapeutics

Founded 2018 · 174 employees on LinkedIn · 2 known investors

Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.

Biotech

Investors · 2

Vida VenturesLos Angeles

Westlake Village BioPartnersLos Angeles · $100K – $5M

Competitors · 1

by search overlap

Bioworld78 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Kyverna Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Kyverna Therapeutics do?: Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Who are Kyverna Therapeutics's investors?: Kyverna Therapeutics's investors include Vida Ventures, Westlake Village BioPartners.